Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition)

Abstract Neutropenia is the most common hematological toxicity of concurrent chemoradiotherapy (CCRT), and leads to subsequent treatment delays and/or dose reductions. often advances febrile neutropenia serious infections, which can affect prognosis safety patients. The reasonable prevention management vital for patients with malignancies undergoing CCRT. Pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF), a long‐acting factor, prevent treat in more convenient clinical settings. Based on relevant guidelines recent data, Chinese Association Therapeutic Radiation Oncologists, China Society Oncology, Therapy have evaluated efficacy PEG‐rhG‐CSF during CCRT, clearly defined pathway route administration neutropenia, formed expert consensus application goal promoting use this treatment.